Completed PHASE4 INTERVENTIONAL NCT00234312

Medications for the Treatment of Dysthymic Disorder and Double Depression

Escitalopram vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression

Sponsor: Forest Laboratories

Interventions escitalopram and sertraline

Updated 6 times since 2017 Last updated: Jul 25, 2019 Started: Sep 30, 2005 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Depression and Dysthymia and is currently completed. Forest Laboratories leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Aug 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jun 2018 — Aug 2019 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
Oregon Health and Science University

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States